What Are FDA Warning Letters?
Warning letters are official FDA communications notifying companies of significant regulatory violations. They are public documents that outline violations and demand corrective action. For the peptide industry, warning letters provide insight into FDA enforcement priorities.
Common Peptide-Related Violations
1. Unapproved New Drug Claims
The most common violation in the peptide space:
- Selling peptides with claims to treat, cure, or prevent disease
- Marketing research chemicals for human use
- Making therapeutic claims without FDA approval
- Website content suggesting medical benefits
2. Compounding Violations
For compounding pharmacies:
- Compounding without valid prescriptions
- Using unapproved bulk drug substances
- Producing "essentially copies" of commercial drugs
- cGMP violations at 503B facilities
- Improper interstate distribution
3. Labeling Violations
- Misbranded products
- Missing required label information
- False or misleading statements
- Inadequate directions for use
4. Manufacturing Violations
- Failure to follow cGMP
- Inadequate quality control testing
- Contamination issues
- Inadequate facility conditions
Recent Enforcement Trends
GLP-1 Compounding Enforcement (2023-2024)
Significant FDA activity around semaglutide and tirzepatide:
- Warning letters to compounders selling GLP-1 medications
- Focus on salt form issues (semaglutide sodium)
- Enforcement against facilities operating outside shortage exception
- Quality concerns with some compounded products
Research Chemical Companies
FDA has targeted companies selling peptides as research chemicals:
- Websites making implicit or explicit health claims
- Customer testimonials suggesting human use
- Dosage information implying human consumption
- Marketing that suggests therapeutic intent
Notable Warning Letter Examples
| Type | Typical Violations | Outcome |
|---|---|---|
| Peptide Seller | Disease claims, unapproved drug | Remove claims, may continue selling as research |
| 503A Pharmacy | Compounding without Rx, wrong substances | Stop violations, state board action |
| 503B Facility | cGMP violations, quality issues | Remediation required, potential shutdown |
| Supplement Company | Peptides in supplements, drug claims | Product recall, reformulation |
How Warning Letters Work
The Process
- Inspection or Investigation: FDA identifies violations
- Warning Letter Issued: Company receives official notice
- Response Required: Usually 15 working days
- Corrective Action: Company must address violations
- Follow-up: FDA verifies compliance
Possible Outcomes
- Close-out Letter: FDA satisfied with response
- Continued Correspondence: Additional corrections needed
- Escalation: Injunction, seizure, or prosecution
- Import Alert: For foreign manufacturers
What Triggers FDA Attention
- Consumer complaints to FDA
- Adverse event reports
- Competitor complaints
- Routine internet surveillance
- State board referrals
- News media coverage
- Scheduled facility inspections
How to Stay Compliant
For Research Chemical Sellers
- Never make health or therapeutic claims
- Label products "for research use only"
- Avoid dosage information suggesting human use
- Don't include customer testimonials about results
- Maintain proper documentation
For Compounding Pharmacies
- Follow 503A or 503B requirements strictly
- Use only approved bulk drug substances
- Maintain valid prescriptions (503A)
- Implement robust quality systems
- Stay current on shortage status
Finding Warning Letters
FDA warning letters are public records:
- FDA Warning Letters Database
- Searchable by company, date, and issue
- Posted approximately 2 weeks after issuance
- Responses are not always public
Legal Implications
Warning letters are serious but are not final agency action:
- Not legally binding determinations
- However, ignoring them often leads to escalation
- Can affect business relationships and banking
- May trigger state regulatory action
- Public nature affects reputation